Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHEZF)

0.7206 0.0000 (0.00%) At close: 09:30AM EDT

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

No. 21 Langshan Road
Nanshan District
Shenzhen 518057
China
86 755 2698 0200
https://www.hepalink.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 2,080

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Li Li	Co-Founder, Chairman of the Board & President	409.23k	N/A	1964
Mr. Yu Shan	Co-Founder, GM, Group VP & Executive Director	364.48k	N/A	1960
Ms. Tan Li	VP, Deputy GM & Director	333.96k	N/A	1964
Ms. Juan Chen	VP of Finance, CFO & Financial Controller	N/A	N/A	1975
Ms. Tao Han M.B.A.	Chief Business Officer	N/A	N/A	N/A
Mr. Ping Zhang	Senior Vice President of Global Industrial Affairs	N/A	N/A	N/A
Mr. Xi Gao	Senior Vice President of Global Supply Chain	N/A	N/A	N/A
Ms. Sze Ting Chan A.C.S.	Joint Company Secretary	N/A	N/A	1982
Mr. Fengqi Qian	Joint Company Secretary	N/A	N/A	1985

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through four segments: Finished dose pharmaceutical products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization, and Others. Its pharmaceutical products consist of finished dose pharmaceutical products, which primarily include enoxaparin sodium injection; API products, including heparin sodium API and enoxaparin sodium API; and other products, such as pancreatin API. The company is also involved in the provision of research and development, manufacturing, quality management, and program management services; and development and manufacture of recombinant pharmaceutical products, critical non-viral vectors, intermediates for gene therapy, and naturally derived pharmaceutical products. In addition, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; research, development, production, and sell of biopharmaceuticals; production and sale of heparin sodium; provision of services on pharmaceutical related activities; and trading of medical and biopharmaceutical products. The company was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, the People's Republic of China.

Corporate governance

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.